Sodium‐glucose co‐transporter‐2 inhibitors in type 2 diabetes: Are clinical trial benefits for heart failure reflected in real‐world clinical practice? A systematic review and meta‐analysis of observational studies
Pooled result · Hospitalization for HFResult — go to the resultHazard ratio 0.65 95% CI 0.59–0.72Authors' conclusion
Real-world SGLT2 inhibitor use supports randomized trial data for the size effect of reduced hospitalization for heart failure in type 2 diabetes, although with a much lower ARR in people without CVD.
Study context
- Population
- People with T2D in observational studies (to 9 May 2022), 17 countries
- Participants
- 4,818,242 people43 studies
- Comparison
- SGLT2i vs no SGLT2i
- Outcome
- Absolute risk reduction of heart failure events (hospitalization for heart failure) per 100 person-years
Methodological detailsrandom-effects models, Newcastle-Ottawa scale bias assessment
- Random-effects models
- Newcastle-Ottawa scale bias assessment
Pooled result
Hospitalization for HF
Hazard ratio
0.65
95% CI 0.59–0.72
SGLT2ivs Comparator
HR 0.65 (95% CI 0.59–0.72)
As reported in the abstract
Further pooled results
| Outcome | HR (95% CI) | |
|---|---|---|
| Hospitalization for HF, subgroup with CVDSGLT2ivs ComparatorARR significantly greater than in those without CVD | 0.78 (0.68–0.89) | |
| Hospitalization for HF, subgroup without CVDSGLT2ivs Comparator | 0.53 (0.39–0.71) | |
| 0.20.5125Hazard ratio (log scale) |
- Hospitalization for HF, subgroup with cardiovascular disease (CVD) — absolute risk reduction (ARR) per 100 person-years
- 1.17 (95% CI 0.78-1.55)
- Hospitalization for HF, subgroup with CVD — NNT to prevent one HF hospitalization, person-years of treatment
- 86 (95% CI 65-128)
- Hospitalization for HF, subgroup without CVD — ARR per 100 person-years
- 0.39 (95% CI 0.32-0.47)
- Hospitalization for HF, subgroup without CVD — NNT to prevent one HF hospitalization, person-years of treatment
- 256 (95% CI 215-316)
Original publication
Sodium‐glucose co‐transporter‐2 inhibitors in type 2 diabetes: Are clinical trial benefits for heart failure reflected in real‐world clinical practice? A systematic review and meta‐analysis of observational studies. Diabetes Obes Metab. Published 2 November 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →